To give a more concrete picture of what NAD injection dosage per day looks like in practice, here is how dosing typically breaks down across the most common program tiers offered by telehealth providers.
Starting Tier — 50 to 100mg Per Injection
Starting tier programs are designed for people who are new to NAD+ injection therapy and want to evaluate their individual response before committing to higher doses. At this tier people typically inject two to three times per week — producing an effective daily average of roughly 15 to 43mg per day. Results at this tier are modest and gradual. This tier is appropriate for general wellness maintenance and people with mild NAD+ depletion who are sensitive to new therapies.
Standard Tier — 250 to 500mg Per Injection
The standard tier is the most common starting point for people pursuing NAD+ therapy for meaningful therapeutic results. At 500mg injected three times per week the effective daily average is approximately 214mg per day. This tier produces noticeable improvements in energy, cognitive function, and physical recovery for most users within the first two to four weeks of a loading protocol. This is the tier most frequently recommended by telehealth providers for people dealing with fatigue, brain fog, or age-related energy decline.
High Dose Tier — 500 to 1000mg Per Injection
High dose protocols are typically reserved for people with significant NAD+ depletion, chronic illness recovery, or those who have completed a standard loading phase and need a more aggressive approach. At 1000mg injected three times per week the effective daily average is approximately 429mg per day. Results at this tier are typically faster and more pronounced — but require careful provider oversight and are generally more expensive on a monthly basis. For a full cost breakdown across tiers see our
NAD Injection Cost guide.
Maintenance Phase Dosing
After completing a loading phase most people transition to maintenance dosing of one to two injections per week at the same milligram strength. This reduces the monthly cost significantly while maintaining the elevated NAD+ baseline established during loading. The transition timing varies by provider and individual response but typically occurs after four to eight weeks of consistent loading phase dosing.